Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.48 |
| ▸ | HRH1 | P35367 | 7/20 | 0.48 |
| ▸ | HTR2B | P41595 | 6/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931067 | 1.00 | MCHR1 (0.48) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Hydrochloric Acid SCHEMBL4919216 | 0.99 | MCHR1 (0.48) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Hydrochloric Acid SCHEMBL4919211 | 0.99 | MCHR1 (0.48) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4928875 | 0.93 | MCHR1 (0.53) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4928869 | 0.93 | MCHR1 (0.53) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Hydrochloric Acid SCHEMBL4925596 | 0.92 | MCHR1 (0.52) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Hydrochloric Acid SCHEMBL4925589 | 0.92 | MCHR1 (0.52) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4924308 | 0.86 | MCHR1 (0.54) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4924327 | 0.86 | MCHR1 (0.54) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4927609 | 0.85 | MCHR1 (0.57) | MCHR1ADRA2AHRH1HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | claimed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | MCHR1 1/4885ADRA2A 133/4885HRH1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.